Portal del Investigador
ADAR-Mediated Regulation of Alternative Splicing as a Primary Driver of Breast Cancer Therapeutic Resistance
Más información
| Fecha de publicación: | 2026 |
| Objetivos: | To establish the ADAR1-splicing axis as a driver of resistance to a broad range of standard of care and novel breast cancer treatments, including cytotoxic, DNA damage-targeted therapies and splicing inhibitors, and to identify specific splice variants that are responsible for this resistance |
| Instrumento: | Fondecyt Regular |
| Año de Inicio/Término: | 2026-2029 |
| Financiamiento/Sponsor: | CONICYT |
| Rol del Usuario: | INVESTIGADOR(A) ASOCIADO(A) |
| URL: | https://www.cienciavida.org/ |
| DOI: |
1261427 |